Revue Neurologique X. Moisset , G. Demarquay, S. de Gaalon, C. Roos, A. Donnet, P. Giraud, E. Guégan-Massardier, C. Lucas, J. Mawet, D. Valade, V. Corand, C. Gollion, N. Moreau, L. Grangeon, M. Lantéri-Minet, A. Ducros Abstract The French migraine
Sumatriptan-naproxen sodium in migraine: A review
European Journal of Neurology 2024 Sep:31 Suppl 2:e16434. doi: 10.1111/ene.16434. Robyn-Jenia Wilcha, Shazia K Afridi , Piero Barbanti, Hans Christoph Diener, Tim Patrick Jürgens, Michel Lanteri-Minet, Christian Lucas, Jerôme Mawet, Xavier Moisset, Antonio Russo, Simona Sacco, Alexandra J Sinclair, Marja-Liisa Sumelahti , Cristina Tassorelli, Peter J Goadsby Abstract Background: Varied responses to acute migraine medications
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A Phase 4, Randomized, Placebo-Controlled Trial
JAMA Neurology 2024 Sep 16:e243043. doi: 10.1001/jamaneurol.2024.3043. Online ahead of print. Stewart J Tepper, David W Dodick, Michel Lanteri-Minet , David Dolezil , Raquel Gil-Gouveia, Christian Lucas, Karolina Piasecka-Stryczynska, Gyöngyi Szabó, Daniel D Mikol, Mahan Chehrenama, Denise E Chou, Yiping Yang, Gabriel Paiva da Silva Lima Abstract Importance: Patients with chronic migraine and medication
Disability in migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study
Cephalalgia 2024 Aug;44(8):3331024241274343. doi: 10.1177/03331024241274343. Zaza Katsarava, Dawn C Buse, Elizabeth Leroux, Michel Lanteri-Minet, Fumihiko Sakai, Manjit S Matharu, Aubrey Manack Adams, Karen Carr, Kristina M Fanning, Richard B Lipton Abstract Background: Few studies of migraine have evaluated migraine disability across multiple countries using the same methodology. Methods: This cross-sectional, web-based
Characterizing barriers to care in migraine: multicountry results from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) study
The journal of headache and pain 2024 Aug 19;25(1):134. doi: 10.1186/s10194-024-01834-y. Michel Lanteri-Minet, Elizabeth Leroux, Zaza Katsarava, Richard B Lipton, Fumihiko Sakai, Manjit Matharu, Kristina Fanning, Aubrey Manack Adams, Katherine Sommer, Michael Seminerio, Dawn C Buse Abstract Objective: To assess rates of traversing barriers to care to access optimal clinical outcomes
Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial
Neurology 2024 Jul 23;103(2):e209584. doi: 10.1212/WNL.0000000000209584. Epub 2024 Jun 26. Peter J Goadsby, Deborah I Friedman, Dagny Holle-Lee, Genevieve Demarquay, Sait Ashina, Fumihiko Sakai, Brian Neel, Pranav Gandhi , Brett Dabruzzo, Jonathan H Smith, Yingyi Liu, Joel M Trugman Abstract Background and objectives: Atogepant is an oral, calcitonin gene-related peptide receptor antagonist approved
Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study
Neurology 2024 May;102(10):e209349. doi: 10.1212/WNL.0000000000209349. Epub 2024 Apr 26. Uwe Reuter, Peter J Goadsby, Michel D Ferrari, Gabriel Paiva Da Silva Lima, Subhayan Mondal, Jawed Kalim, Fatima Hasan, Shihua Wen, Michal Arkuszewski, Shaloo Pandhi, Tracy Stites, Michel Lanteri-Minet Abstract Background and objectives: The LIBERTY study assessed the efficacy and safety of erenumab
The use of the term “migraineur” in the modern scientific literature
Pain practice : the official journal of World Institute of Pain 2024 Apr 6. doi: 10.1111/papr.13375. Online ahead of print. Sylvain Redon, Anne Donnet No abstract available PMID: 38581232 DOI: 10.1111/papr.13375
Patient Sex in Prescribing CGRP Receptor Antagonists for Migraine
JAMA Neurology JAMA Neurol. Published online February 26, 2024. doi:10.1001/jamaneurol.2023.5835 Michel Lanteri-Minet; Shuu-Jiun Wang; Paolo Martelletti To the Editor In a recent JAMA Neurology Viewpoint,1 Porreca and Dodick raised an important issue by discussing gender differences in outcomes of calcitonin
Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial
The Lancet Neurology 2024 Feb 13:S1474-4422(24)00025-5. doi: 10.1016/S1474-4422(24)00025-5. Cristina Tassorelli, Krisztián Nagy, Patricia Pozo-Rosich, Michel Lanteri-Minet, Sara Sacco, Tomáš Nežádal, Hua Guo, Rosa De Abreu Ferreira, Giovanna Forero, Joel M Trugman Abstract Background: Atogepant, an oral calcitonin gene-related peptide receptor antagonist, has been approved for the preventive treatment of